A phase 2a multi-center, randomized, double-blind, placebo-controlled, dose ranging study evaluated the efficacy of GSK2586184 in 66 patients with chronic plaque psoriasis. Compared to placebo, a significantly higher proportion of patients treated with the investigational drug met the primary endpoint of achieving 75% improvement from baseline in Psoriasis Area Severity Index score at week 12. This is the second selective JAK1 (janus kinase) inhibitor in development, representing a novel approach to anti-inflammatory therapy. GSK will review the complete data from all GSK2586184 studies before advancing to phase 3 study. What are your thoughts about this novel pharmacotherapy? #ipharm

For additional information, please see the article in Reuters.
Click for more information from Galapagos.

Image courtesy of [phasinphoto]/FreeDigitalPhotos.Net